Form 4: Silence Therapeutics Director Reports Internal Share Transfers

Silence Therapeutics director Richard Ian Griffiths reported internal transfers of American Depositary Shares, maintaining his overall beneficial ownership.

Summary

• Richard Ian Griffiths, a Director and 10% Owner of Silence Therapeutics plc (SLN), filed a Form 4 detailing transactions involving American Depositary Shares (ADS).
• On August 3, 2025, 20,000 ADSs (representing 60,000 Ordinary Shares) were sold at $5.45 and simultaneously purchased at the same price.
• On October 27, 2025, 2,000 ADSs (representing 6,000 Ordinary Shares) were sold at $7.75 and simultaneously purchased at the same price.
• These transactions were described as 'internal transfers' between Ora Capital Limited (OCL) and Mr. Griffiths personally.
• Mr. Griffiths is a director and the controlling shareholder of OCL.
• There was 'no change in total beneficial holding' for Mr. Griffiths as a result of these transactions.
• Each American Depositary Share (ADS) is immediately convertible into three ordinary shares for no consideration and has no expiration date.
• Following these reported transactions, Mr. Griffiths indirectly beneficially owns 11,825,861 Ordinary Shares (via ADSs).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the reported transactions are internal transfers between entities controlled by the reporting person, resulting in no net change in beneficial ownership.

Positives

• No net change in the beneficial ownership of a significant insider, indicating no sell-off of shares.

Negatives

• No new investment or increase in beneficial ownership by the insider was reported.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Management Comments

• "The securities were sold by Ora Capital Limited ("OCL") and purchased by Mr. Griffiths personally, essentially internal transfers with no change in total beneficial holding."
• "Mr Griffiths is a director and the controlling shareholder of OCL."
• "Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein."

Industry Context

StockSavvy.ai notes that internal transfers of securities by insiders, especially between entities they control and themselves, are common administrative actions and typically do not reflect a change in investment sentiment or strategic direction for the company or the broader biotechnology industry.

Related Party Transactions

• The reported transactions between Ora Capital Limited (OCL) and Mr. Griffiths personally are considered related party dealings, as Mr. Griffiths is the controlling shareholder and director of OCL.

Stakeholder Impact

• Minimal impact on shareholders, employees, customers, suppliers, or creditors, as these are internal transfers with no change in overall beneficial ownership by the insider.

Key Dates

Keywords

Silence Therapeutics, SLN, Richard Ian Griffiths, Form 4, insider transaction, beneficial ownership, American Depositary Shares, ADS, Ordinary Shares, director, 10% owner, Ora Capital Limited